121 related articles for article (PubMed ID: 7444140)
1. Quelamycin: a summary of phase I clinical trials.
Cortés-Funes H; Brugarolas A; Gosálvez M
Recent Results Cancer Res; 1980; 74():200-6. PubMed ID: 7444140
[TBL] [Abstract][Full Text] [Related]
2. Early clinical trial with quelamycin.
Cortés-Funes H; Gosálvez M; Moyano A; Mañas A; Mendiola C
Cancer Treat Rep; 1979 May; 63(5):903-8. PubMed ID: 455331
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical study of quelamycin.
Brugarolas A; Pachon N; Gosalvez M; Llanderal AP; Lacave AJ; Buesa JM; Marco MG
Cancer Treat Rep; 1978 Oct; 62(10):1527-34. PubMed ID: 361226
[TBL] [Abstract][Full Text] [Related]
4. Iron toxicity studies of quelamycin.
Brugarolas A; Perez Llanderal JA; Garcia Miralles MT; Lacave AJ; Gracia Marco M; Izquierdo JM; Rodriguez Llorian AC; Ribas A
Cancer Treat Rep; 1979 May; 63(5):909-13. PubMed ID: 455332
[TBL] [Abstract][Full Text] [Related]
5. Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia.
Bonfante V; Bonadonna G; Villani F; Martini A
Recent Results Cancer Res; 1980; 74():192-9. PubMed ID: 6934564
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
Lyseng-Williamson KA; Duggan ST; Keating GM
BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
Fiore J; Kemeny N; Raymond V; Young C
Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
[No Abstract] [Full Text] [Related]
8. Phase I study of pirarubicin.
Miller AA; Scheulen ME; Kleeberg UR; Seeber S; Schmidt CG
J Cancer Res Clin Oncol; 1988; 114(1):91-4. PubMed ID: 3162456
[TBL] [Abstract][Full Text] [Related]
9. Quelamycin, a new derivative of adriamycin with several possible therapeutic advantages.
Gosálvez M; Blanco MF; Vivero C; Vallés F
Eur J Cancer (1965); 1978 Nov; 14(11):1185-90. PubMed ID: 216553
[No Abstract] [Full Text] [Related]
10. Phase II trial of 4'epi-adriamycin for advanced hypernephroma.
Benedetto P; Ahmed T; Needles B; Watson RC; Yagoda A
Am J Clin Oncol; 1983 Oct; 6(5):553-4. PubMed ID: 6577784
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of Doxorubicin (Dox) to different experimental organ systems.
Pugazhendhi A; Edison TNJI; Velmurugan BK; Jacob JA; Karuppusamy I
Life Sci; 2018 May; 200():26-30. PubMed ID: 29534993
[TBL] [Abstract][Full Text] [Related]
12. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
13. Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.
Kolarić K; Potrebica V; Cervek J
J Cancer Res Clin Oncol; 1983; 106(2):148-52. PubMed ID: 6579052
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
[TBL] [Abstract][Full Text] [Related]
15. [A phase I trial of 4'-epiadriamycin].
Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
[TBL] [Abstract][Full Text] [Related]
16. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
17. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
Green JB; Green S; O'Toole RV; Alberts DS; Nahhas WA; Wallace DL
Invest New Drugs; 1991 May; 9(2):191-3. PubMed ID: 1874602
[TBL] [Abstract][Full Text] [Related]
18. A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
Martoni A; Giovannini M; Tomasi L; Camaggi CM; Bellanova B; Monetti N; Rossini G; Tarquinii M; Martini A; Pannuti F
Cancer Chemother Pharmacol; 1984; 12(3):179-82. PubMed ID: 6584236
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline cardiotoxicity and its prevention.
Mott MG
Ann N Y Acad Sci; 1997 Sep; 824():221-8. PubMed ID: 9382447
[No Abstract] [Full Text] [Related]
20. Troponins for predicting cardiotoxicity from cancer therapy.
Sparano JA; Wolff AC; Brown D
Lancet; 2000 Dec; 356(9246):1947-8. PubMed ID: 11130520
[No Abstract] [Full Text] [Related]
[Next] [New Search]
